Impact of the COVID-19 pandemic on multiple myeloma treatment

Managing Patients With Multiple Myeloma in the COVID-19 EnvironmentПодробнее

Exciting Myeloma Treatments in 2023: Longer Remissions and Better Outcomes! | The Patient StoryПодробнее

Results of Maintenance Therapy in High-Risk Myeloma Patients | Ajay Nooka, MD, MPH, FACP | ASCO 2023Подробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее

ASH Update #3 - the ASCENT trial - Dara-KRD in smoldering myeloma - It can't assess cure. Bad trialПодробнее

All about IVIG (Intravenous Immunoglobulin) for Myeloma PatientsПодробнее

Multiple Myeloma: A Patient’s ExperienceПодробнее

Myeloma Patients are Having LONGER Remissions with this Game Changing Treatment! | The Patient StoryПодробнее

Multiple Myeloma: Should I Get Vaccinated? | The Patient StoryПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

MPE Masterclass 2022 | Latest updates on COVID-19 and its impact on myeloma patientsПодробнее

11th Annual Hicks Harris Ferguson Multiple Myeloma SymposiumПодробнее

Adapting the PERCEPT myeloma prehabilitation trial to virtual delivery during the COVID-19 pandemicПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Impact of COVID-19 on treatment patterns and management of multiple myelomaПодробнее

COVID-19 and Multiple Myeloma: Clifton Mo, MDПодробнее

The importance of improving the efficacy of COVID-19 vaccination in patients with myelomaПодробнее

Ivermectin clarificationПодробнее

Multiple Myeloma, Covid-19, Vaccinations, and BoostersПодробнее

The impact of the COVID-19 pandemic on myeloma treatmentПодробнее